ArticleFrontiers in immunology2026
Bioactive compound ginkgolide B alleviates food allergy by regulating mTOR signaling pathway.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of food allergy has been rising over the past decade, but effective treatments remain limited. The purpose of this study was to investigate the effect of ginkgolide B (GB), a natural bioactive compound with well-documented anti-inflammatory and immunoregulatory properties, on a mouse model of food allergy and to elucidate the mechanism mediated by the mTOR signaling pathway. Methods: BALB/c mice were randomly divided into five groups, namely: NC group, food allergy group (Model), low-dose GB intervention group (GBL, 5 mg/kg/day), high-dose GB intervention group (GBH, 40 mg/kg/day), and a positive control group treated with food allergy herbal formula-2 (FAHF-2). At the end of the sensitization period, the mice were intervened by gavaging GB or FAHF-2. Allergy-related factors such as serum titers, cytokines in the spleen, and intestinal morphology were detected. mTOR signaling pathway in the splenocytes was also detected. Results: After treatment, the levels of serum IgE, IgG, IgG1, and IgG2a in the GBL group were significantly lower than those in the GBH and model groups. The analysis of intestinal morphology indicated that a low dose of GB and FAHF-2 alleviated food allergy more effectively than a high dose of GB. The results of the analysis of splenic cytokines and flow cytometry showed more balanced Th1/Th2 ratio and Th17/Treg ratio after GB and FAHF-2 treatment, especially for GBL, whose effect was comparable to those of FAHF-2. The expression levels of p-STAT3, p-STAT6, and GATA-3 were significantly decreased, and the expression levels of p-STAT4 and Foxp3 were significantly increased after GB and FAHF-2 treatment. Moreover, the reductions in p-mTOR, p-AKT, p-SGK1, and p-4EBP1 induced by allergic sensitization were restored in the GBL intervention group. Conclusion: GB (5 mg/kg/day) exerts a significant therapeutic effect on food allergy, possibly by regulating the mTOR signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.